Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2006-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-05-0147PMID 16546981
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti-Versus Pro-apoptotic Effects of Estrogens*

  2005cited by this paper
• Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein.

  2005influential reference
• Proteasome inhibition as a novel therapeutic target in human cancer.

  2005cited by this paper
• Putting the rap on Akt.

  2004cited by this paper
• Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

  2004cited by this paper
• Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

  2004cited by this paper
• A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC).

  2004cited by this paper
• Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ubiquitination of histones and type I inositol 1,4,5-trisphosphate receptor.

  2004cited by this paper
• A phase II trial of PS-341 in metastatic breast cancer (MBC).

  2004cited by this paper
• Targeting the ubiquitin-proteasome pathway in breast cancer.

  2004cited by this paper
• The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.

  2004cited by this paper
• Evidence That Mitogen-Activated Protein Kinase Phosphatase-1 Induction by Proteasome Inhibitors Plays an Antiapoptotic Role

  2004cited by this paper
• Targeted therapies for cancer 2004.

  2004cited by this paper
• Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.

  2004cited by this paper
• Use of Methotrexate-Based Peptide Substrates to Characterize the Substrate Specificity of Prostate-Specific Membrane Antigen (PSMA)

  2004cited by this paper
• The proteasome: a suitable antineoplastic target

  2004cited by this paper
• Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma

  2004cited by this paper
• The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor zenografts

  2004cited by this paper
• Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.

  2004cited by this paper
• Proteasome and histone deacetylase inhibitors repress ErbB2 transcript levels and additively inhibit breast cancer growth.

  2004cited by this paper
• The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

  2003cited by this paper
• Cross-Talk Between Growth Factor and Progesterone Receptor Signaling Pathways: Implications for Breast Cancer Cell Growth

  2003cited by this paper
• Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.

  2003cited by this paper
• Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.

  2003cited by this paper
• ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

  2003cited by this paper
• Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Mouse models of human breast cancer: evolution or convolution?

  2003cited by this paper
• Evidence That Inhibition of p44/42 Mitogen-activated Protein Kinase Signaling Is a Factor in Proteasome Inhibitor-mediated Apoptosis*

  2002cited by this paper
• Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies

  2002cited by this paper
• The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer

  2002cited by this paper
• Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

  2001cited by this paper
• Biology of HER2 and Its Importance in Breast Cancer

  2001cited by this paper
• The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma

  2000cited by this paper
• Proteasome inhibition measurements: clinical application.

  2000cited by this paper
• The proteasome controls the expression of a proliferation‐associated nuclear antigen Ki‐67

  2000cited by this paper
• The proteasome: a macromolecular assembly designed for controlled proteolysis.

  1999cited by this paper
• The ErbB Receptors as Targets for Breast Cancer Therapy

  1999cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper
• p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.

  1999cited by this paper
• Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

  1999cited by this paper
• The ubiquitin–proteasome pathway: on protein death and cell life

  1998cited by this paper
• Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

  1998cited by this paper
• Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents

  1996cited by this paper
• Microculture tetrazolium assays: a comparison between two new tetrazolium salts, XTT and MTS.

  1995cited by this paper
• Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

  1995cited by this paper
• Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

  1993cited by this paper
• Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells.

  1991cited by this paper

• Boron-containing anticancer agents: a target-centric review of structure–activity relationships and clinical pipeline

  2025cites this paper
• The Transcription Axes ERK-Elk1, JNK-cJun, and JAK-STAT Promote Autophagy Activation and Proteasome Inhibitor Resistance in Prostate Cancer Cells

  2025cites this paper
• Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer

  2024cites this paper
• The ERK1/2-Elk1, JNK-cJun, and JAK-STAT Transcriptional Axes as Potential Bortezomib Resistance Mediators in Prostate Cancer

  2024cites this paper
• Sialic Acid Engineered Prodrug Nanoparticles for Codelivery of Bortezomib and Selenium in Tumor Bearing Mice.

  2023cites this paper
• Modulation of the ubiquitin‐proteasome system by phytochemicals: Therapeutic implications in malignancies with an emphasis on brain tumors

  2023cites this paper
• Angiopep-2 Grafted PAMAM Dendrimers for the Targeted Delivery of Temozolomide: In Vitro and In Vivo Effects of PEGylation in the Management of Glioblastoma Multiforme.

  2023cites this paper
• Opposing effects of metformin mediated mTORC1 inhibition on IRES possessing anti-apoptotic proteins in breast cancer cell lines.

  2022cites this paper
• Non-viral inducible caspase 9 mRNA delivery using lipid nanoparticles against breast cancer: An in vitro study.

  2022cites this paper
• Proteostasis regulators modulate proteasomal activity and gene expression to attenuate multiple phenotypes in Fabry disease

  2020cites this paper
• Graph convolutional networks for drug response prediction

  2020cites this paper
• Biotinylated HPMA Centered Polymeric Nanoparticles for Bortezomib Delivery.

  2020cites this paper
• Emerging drug development technologies targeting ubiquitination for cancer therapeutics

  2019cites this paper
• Endoplasmic Reticulum (ER) Reorganization and Intracellular Retention of CD58 Are Functionally Independent Properties of the Human Cytomegalovirus ER-Resident Glycoprotein UL148

  2019cites this paper
• Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation

  2019cites this paper
• VDR agonists down regulate PI3K/Akt/mTOR axis and trigger autophagy in Kaposi's sarcoma cells

  2019cites this paper
• HYPOXIA-MEDIATED INVASIVENESS AND METASTASIS: FOCUS ON CANINE AND HUMAN MAMMARY TUMORS The relationship of COX-2 and the mammary carcinomas in dogs

  2018cites this paper
• Proteasome‐mediated proteostasis: Novel medicinal and pharmacological strategies for diseases

  2018cites this paper
• Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy

  2018cites this paper
• Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells

  2017cites this paper
• Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis.

  2017cites this paper
• Proteasome Stress Triggers Death of SH-SY5Y and T98G Cells via Different Cellular Mechanisms

  2017cites this paper
• Curcumin-bortezomib loaded polymeric nanoparticles for synergistic cancer therapy

  2017cites this paper
• Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma

  2016cites this paper
• Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity

  2016cites this paper
• c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer

  2016cites this paper
• Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption

  2016cites this paper
• Triomics Analysis of Imatinib-Treated Myeloma Cells Connects Kinase Inhibition to RNA Processing and Decreased Lipid Biosynthesis.

  2015cites this paper
• Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.

  2015cites this paper
• Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms

  2015cites this paper
• The Future of Boron in Medicinal Chemistry: Therapeutic and Diagnostic Applications

  2015cites this paper
• Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.

  2015cites this paper
• Linking the activity of bortezomib in multiple myeloma and autoimmune diseases.

  2014cites this paper
• Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation

  2014cites this paper
• Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells

  2014cites this paper
• Analysis of signaling pathways in recurrent breast cancer.

  2014cites this paper
• Inhibition of Nek2 by Small Molecules Affects Proteasome Activity

  2014cites this paper
• Effects of an Anticarcinogenic Bowman-Birk Protease Inhibitor on Purified 20S Proteasome and MCF-7 Breast Cancer Cells

  2014cites this paper
• Nrf2- and ATF4-Dependent Upregulation of xCT Modulates the Sensitivity of T24 Bladder Carcinoma Cells to Proteasome Inhibition

  2014cites this paper
• Drug combinations with proteasome inhibitors in antitumor therapy.

  2013cites this paper
• Neziskové léky: Aktivita komplexu disulfiramu (antabusu) s mědí proti buněčné linii odvozené od osteosarkomu

  2013cites this paper
• CXCR4 is a good survival prognostic indicator in multiple myeloma patients.

  2013cites this paper
• Erratum to: Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

  2013cites this paper
• Bortezomib Congeners Induce Apoptosis of Hepatocellular Carcinoma via CIP2A Inhibition

  2013cites this paper
• Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines

  2013cites this paper
• Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes

  2013cites this paper
• Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts

  2013cites this paper
• Boron chemicals in diagnosis and therapeutics.

  2013cites this paper
• Inactivation of the mTORC1-Eukaryotic Translation Initiation Factor 4E Pathway Alters Stress Granule Formation

  2013cites this paper
• Dynamics of tumor progression and therapy response in Il-6 and Myc driven plasma cell malignancy

  2013cites this paper
• Targeting the proteasome as a promising therapeutic strategy in thyroid cancer

  2012cites this paper
• Efecto de la doxorubicina sobre MKP-1 en el cáncer de mama humano y asociación entre la expresión de MKP-1 y la evolución de las pacientes

  2012cites this paper
• Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells.

  2012cites this paper
• Proteasome Inhibition Reduces Proliferation, Collagen Expression, and Inflammatory Cytokine Production in Nasal Mucosa and Polyp Fibroblasts

  2012influential citation
• CIP2A is a target of bortezomib in human triple negative breast cancer cells

  2012cites this paper
• Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration.

  2011cites this paper
• Current options in breast cancer targeted therapies: life after HER-2.

  2011cites this paper
• p21WAF1/CIP1 Upregulation through the Stress Granule-Associated Protein CUGBP1 Confers Resistance to Bortezomib-Mediated Apoptosis

  2011cites this paper
• Boron Compounds in the Breast Cancer Cells Chemoprevention and Chemotherapy

  2011cites this paper
• Antitumor activity of efrapeptins, alone or in combination with 2-deoxyglucose, in breast cancer in vitro and in vivo

  2011cites this paper
• Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.

  2011cites this paper
• Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

  2011cites this paper
• MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines

  2011cites this paper
• Polysaccharide-gold nanoparticles as anticancer drugs carriers

  2011cites this paper
• The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.

  2011cites this paper
• Influence of proteasome inhibitor bortezomib on the expression of multidrug resistance genes and Akt kinase activity

  2011cites this paper
• Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells

  2010cites this paper
• Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types

  2010cites this paper
• Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

  2010cites this paper
• The chemotherapeutic agent bortezomib induces the formation of stress granules

  2010cites this paper
• Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress, and induces caspase-dependent cell death in antiestrogen–sensitive and resistant ER+ breast cancer cells

  2010cites this paper
• MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype.

  2010cites this paper
• Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and "triple-negative" breast cancers.

  2010cites this paper
• Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)‐overexpressing breast cancer cells and activity of bortezomib against lapatinib‐resistant breast cancer cells

  2010cites this paper
• Open Access PRIMARY RESEARCH

  2010cites this paper
• Molekulare Therapie des Mantelzelllymphoms - In Vitro Wirksamkeit des Proteasom-Inhibitors Bortezomib in Mono- und Kombinationstherapie

  2010cites this paper
• Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an In vitro Lung Carcinogenesis System

  2009cites this paper
• Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells

  2009cites this paper
• A proteomic study on a human osteosarcoma cell line Saos-2 treated with diallyl trisulfide

  2009cites this paper
• Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin

  2009cites this paper
• Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non–Small Cell Lung Cancer

  2009cites this paper
• Sensitization of human breast cancer cells to natural killer cell‐mediated cytotoxicity by proteasome inhibition

  2009cites this paper
• Proteasome inhibition represses ERα gene expression in ER+ cells- a new link between proteasome activity and estrogen signaling in breast cancer

  2009cites this paper
• The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.

  2009cites this paper
• Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents

  2009cites this paper
• The cytotoxicity of γ-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by γ-secretase inhibition

  2009influential citation
• Inhibition of the JNK signalling pathway enhances proteasome inhibitor‐induced apoptosis of kidney cancer cells by suppression of BAG3 expression

  2009cites this paper
• Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway*

  2009cites this paper
• Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.

  2008cites this paper
• Synergistic anti‐proliferative and pro‐apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti‐epidermal growth factor receptor (EGFR) drugs in human cancer cells

  2008influential citation
• Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.

  2008cites this paper
• A NOVEL CLASS OF IMMUNOPROTEASOME CATALYTIC SUBUNIT LMP2 INHIBITOR AND ITS THERAPEUTIC POTENTIALS IN CANCER

  2008cites this paper
• Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model

  2008cites this paper
• Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.

  2008cites this paper
• Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways

  2008cites this paper
• The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

  2008cites this paper
• Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options

  2008cites this paper
• Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

  2008cites this paper
• Signaling Pathways in Pancreatic Cancer Cells Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Proteasome Inhibition Activates Epidermal Growth Factor

  2008cites this paper
• BU-32: a novel proteasome inhibitor for breast cancer

  2008cites this paper